193 related articles for article (PubMed ID: 38106909)
1. Evolving trends among
Thomsen J; Menezes GA; Abdulrazzaq NM; ; Moubareck CA; Senok A; Everett DB
Front Public Health; 2023; 11():1243973. PubMed ID: 38106909
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology and antimicrobial resistance trends of
Thomsen J; Abdulrazzaq NM; AlRand H; ; Everett DB; Senok A; Menezes GA; Ayoub Moubareck C
Front Public Health; 2023; 11():1245131. PubMed ID: 38239785
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of vancomycin-resistant enterococci in the United Arab Emirates: a retrospective analysis of 12 years of national AMR surveillance data.
Thomsen J; Abdulrazzak NM; AlRand H; ; Menezes GA; Moubareck CA; Everett DB; Senok A; Podbielski A
Front Public Health; 2023; 11():1275778. PubMed ID: 38089023
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and antimicrobial resistance of
Thomsen J; Abdulrazzaq NM; Nyasulu PS; Al Hosani F; Habous M; Weber S; Jabeen F; ; Menezes GA; Moubareck CA; Senok A; Everett DB
Front Public Health; 2024; 12():1244353. PubMed ID: 38947352
[TBL] [Abstract][Full Text] [Related]
5. Carbapenem resistant
Thomsen J; Abdulrazzaq NM; ; Everett DB; Menezes GA; Senok A; Ayoub Moubareck C
Front Public Health; 2023; 11():1244482. PubMed ID: 38145078
[TBL] [Abstract][Full Text] [Related]
6. Emergence of highly resistant
Thomsen J; Abdulrazzaq NM; Oulhaj A; Nyasulu PS; Alatoom A; Denning DW; Al Dhaheri F; ; Menezes GA; Moubareck CA; Senok A; Everett DB
Front Public Health; 2023; 11():1244358. PubMed ID: 38292390
[TBL] [Abstract][Full Text] [Related]
7. Methicillin resistant
Thomsen J; Abdulrazzaq NM; ; Menezes GA; Ayoub Moubareck C; Everett DB; Senok A
Front Public Health; 2023; 11():1244351. PubMed ID: 38145065
[TBL] [Abstract][Full Text] [Related]
8. Surveillance of antimicrobial resistance in the United Arab Emirates: the early implementation phase.
Thomsen J; Abdulrazzaq NM; AlRand H;
Front Public Health; 2023; 11():1247627. PubMed ID: 38074700
[TBL] [Abstract][Full Text] [Related]
9. Distribution of carbapenem resistance mechanisms in clinical isolates of XDR Pseudomonas aeruginosa.
De Rosa A; Mutters NT; Mastroianni CM; Kaiser SJ; Günther F
Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1547-1552. PubMed ID: 31152264
[TBL] [Abstract][Full Text] [Related]
10. Identification of carbapenem-resistant Pseudomonas aeruginosa in selected hospitals of the Gulf Cooperation Council States: dominance of high-risk clones in the region.
Zowawi HM; Syrmis MW; Kidd TJ; Balkhy HH; Walsh TR; Al Johani SM; Al Jindan RY; Alfaresi M; Ibrahim E; Al-Jardani A; Al Salman J; Dashti AA; Sidjabat HE; Baz O; Trembizki E; Whiley DM; Paterson DL
J Med Microbiol; 2018 Jun; 67(6):846-853. PubMed ID: 29664716
[TBL] [Abstract][Full Text] [Related]
11. Carbapenem-resistant
Huang W; Wei X; Xu G; Zhang X; Wang X
Front Public Health; 2023; 11():1088262. PubMed ID: 36844819
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of Multidrug-Resistant Pseudomonas aeruginosa in the Middle East and North Africa Region.
Al-Orphaly M; Hadi HA; Eltayeb FK; Al-Hail H; Samuel BG; Sultan AA; Skariah S
mSphere; 2021 May; 6(3):. PubMed ID: 34011686
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, Risk Factors, and Molecular Epidemiology of Intestinal Carbapenem-Resistant Pseudomonas aeruginosa.
Hu Y; Qing Y; Chen J; Liu C; Lu J; Wang Q; Zhen S; Zhou H; Huang L; Zhang R
Microbiol Spectr; 2021 Dec; 9(3):e0134421. PubMed ID: 34817230
[TBL] [Abstract][Full Text] [Related]
14. Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa in Children, United States, 1999-2012.
Logan LK; Gandra S; Mandal S; Klein EY; Levinson J; Weinstein RA; Laxminarayan R;
J Pediatric Infect Dis Soc; 2017 Nov; 6(4):352-359. PubMed ID: 27856730
[TBL] [Abstract][Full Text] [Related]
15. Eight-year trends in the relative isolation frequency and antimicrobial susceptibility among bloodstream isolates from Greek hospitals: data from the Greek Electronic System for the Surveillance of Antimicrobial Resistance - WHONET-Greece, 2010 to 2017.
Polemis M; Tryfinopoulou K; Giakkoupi P; ; Vatopoulos A
Euro Surveill; 2020 Aug; 25(34):. PubMed ID: 32856583
[TBL] [Abstract][Full Text] [Related]
16.
Shortridge D; Streit JM; Mendes R; Castanheira M
Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
[TBL] [Abstract][Full Text] [Related]
17. The impact of multi-drug resistant Pseudomonas aeruginosa infections on acute pancreatitis patients.
Wu D; Lu W; Huang Y; Qin G; Liu H; Xiao J; Peng J
BMC Infect Dis; 2023 May; 23(1):340. PubMed ID: 37217844
[TBL] [Abstract][Full Text] [Related]
18. Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients: risk factors and outcomes.
Shanthi M; Sekar U
J Assoc Physicians India; 2009 Sep; 57():636, 638-40, 645. PubMed ID: 20214000
[TBL] [Abstract][Full Text] [Related]
19. Carbapenem Resistant
Qin J; Zou C; Tao J; Wei T; Yan L; Zhang Y; Wang H
Infect Drug Resist; 2022; 15():2301-2314. PubMed ID: 35517901
[TBL] [Abstract][Full Text] [Related]
20. MDR/XDR/PDR or DTR? Which definition best fits the resistance profile of Pseudomonas aeruginosa?
Cosentino F; Viale P; Giannella M
Curr Opin Infect Dis; 2023 Dec; 36(6):564-571. PubMed ID: 37930070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
